Skip to main content

Table 3 Changes in urinary excretion of 8-iso-PGF2α at day 28

From: Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

  Placebo (n = 20) Empagliflozin 10 mg (n = 20) Empagliflozin 25 mg (n = 19)
Fasting state, pg/ml    
Baseline 197.8 (27.0) 194.6 (29.4) 146.5 (18.5)
Change from baseline at day 28 40.6 (22.6) −48.1 (23.3) −33.5 (23.7)
 Difference vs placebo (95% CI)   −88.6 (−154.6, −22.7) −74.0 (−139.8, −8.2)
 p-value   0.010 0.028
In 24 hours after drug administration, pg/ml    
Baseline 115.5 (11.0) 138.3 (20.6) 148.6 (21.7)
Change from baseline at day 28 −3.7 (10.3) −28.4 (10.4) −46.8 (10.6)
 Difference vs placebo (95% CI)   −24.7 (−54.5, 5.2) −43.1 (−72.9, −13.3)
 p-value   0.103 0.006
  1. Baseline data are mean (standard error [SE]), change from baseline data are adjusted mean (SE) based on analysis of covariance (ANCOVA) in the full analysis set.